{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:07:17Z","timestamp":1774512437975,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Axillary staging is commonly performed in patients with clinically node-positive (cN+) breast cancer undergoing neoadjuvant chemotherapy (NACT), regardless of pathological complete response (pCR). Recent evidence has suggested that ypT0 correlates with ypN0 and favorable prognosis, potentially supporting the omission of axillary staging in such cases. This study aimed to evaluate ypT0 as a predictive factor for ypN status and its prognostic significance in cN+ breast cancer treated with NACT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included 302 patients with cN+ breast cancer treated with NACT at Hiroshima University Hospital between 2006 and 2022. Patients were categorized into non-pCR, ypTis, or ypT0 based on ypT status. Associations between breast pCR, ypN status, recurrence-free survival (RFS), and overall survival (OS) were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 302 patients (non-pCR, 74.2%; ypTis, 8.9%; ypT0, 16.9%), the ypN+ rates were 63.3%, 15.2%, and 3.9%, respectively. Logistic regression revealed significant associations among ypT0, ypTis, and ypN0. The five-year RFS and OS rates were 78.6% and 85.2% (non-pCR), 83.8% and 95.5% (ypTis), and 98.0% and 100.0% (ypT0), respectively. Cox regression identified ypT0, but not ypTis, as a significant prognostic factor for both RFS and OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>ypT0 status was associated with a low risk of ypN+ and favorable clinical outcomes in cN+ breast cancer, suggesting the potential feasibility of omitting axillary surgery in select patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10549-025-07697-4","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T05:31:58Z","timestamp":1744435918000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy"],"prefix":"10.1007","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-9655","authenticated-orcid":false,"given":"Hideo","family":"Shigematsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Takaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsumi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Ikejiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Amioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Arihiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"7697_CR1","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/bjs.11653","volume":"107","author":"L Niinikoski","year":"2020","unstructured":"Niinikoski L, Hukkinen K, Leidenius MHK, Heikkila P, Mattson J, Meretoja TJ (2020) Axillary nodal metastatic burden in patients with breast cancer with clinically positive axillary nodes. Br J Surg 107:1615\u20131624. https:\/\/doi.org\/10.1002\/bjs.11653","journal-title":"Br J Surg"},{"key":"7697_CR2","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1200\/JCO.2002.09.018","volume":"20","author":"W Kwan","year":"2002","unstructured":"Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA (2002) Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 20:4242\u20134248. https:\/\/doi.org\/10.1200\/JCO.2002.09.018","journal-title":"J Clin Oncol"},{"key":"7697_CR3","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1245\/s10434-009-0452-2","volume":"16","author":"RJ Tsai","year":"2009","unstructured":"Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C (2009) The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 16:1959\u20131972. https:\/\/doi.org\/10.1245\/s10434-009-0452-2","journal-title":"Ann Surg Oncol"},{"key":"7697_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol 39:1485\u20131505. https:\/\/doi.org\/10.1200\/JCO.20.03399","journal-title":"J Clin Oncol"},{"key":"7697_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Burstein HJ, Gnant M et al (2023) Understanding breast cancer complexity to improve patient outcomes: The St Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol 34:970\u2013986. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.017","journal-title":"Ann Oncol"},{"key":"7697_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","volume":"17","author":"M Untch","year":"2016","unstructured":"Untch M, Jackisch C, Schneeweiss A et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17:345\u2013356. https:\/\/doi.org\/10.1016\/S1470-2045(15)00542-2","journal-title":"Lancet Oncol"},{"key":"7697_CR7","doi-asserted-by":"publisher","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","volume":"6","author":"Z Shao","year":"2020","unstructured":"Shao Z, Pang D, Yang H et al (2020) Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol 6:e193692. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3692","journal-title":"JAMA Oncol"},{"key":"7697_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","volume":"22","author":"AR Tan","year":"2021","unstructured":"Tan AR, Im SA, Mattar A et al (2021) Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol 22:85\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(20)30536-2","journal-title":"Lancet Oncol"},{"key":"7697_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"7697_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S et al (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152:665\u2013670. https:\/\/doi.org\/10.1001\/jamasurg.2017.0562","journal-title":"JAMA Surg"},{"key":"7697_CR11","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","volume":"28","author":"A Weiss","year":"2021","unstructured":"Weiss A, Campbell J, Ballman KV et al (2021) Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (triple-negative) (alliance). Ann Surg Oncol 28:5960\u20135971. https:\/\/doi.org\/10.1245\/s10434-021-09897-w","journal-title":"Ann Surg Oncol"},{"key":"7697_CR12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","volume":"153","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC (2018) Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg 153:1120\u20131126. https:\/\/doi.org\/10.1001\/jamasurg.2018.2696","journal-title":"JAMA Surg"},{"key":"7697_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123698","author":"T Reimer","year":"2020","unstructured":"Reimer T, Glass A, Botteri E, Loibl S, Gentilini OD (2020) Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST-01 trial. Cancers. https:\/\/doi.org\/10.3390\/cancers12123698","journal-title":"Cancers"},{"key":"7697_CR14","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","volume":"26","author":"V Bossuyt","year":"2015","unstructured":"Bossuyt V, Provenzano E, Symmans WF et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 26:1280\u20131291. https:\/\/doi.org\/10.1093\/annonc\/mdv161","journal-title":"Ann Oncol"},{"key":"7697_CR15","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1200\/JCO.2006.08.2271","volume":"25","author":"C Mazouni","year":"2007","unstructured":"Mazouni C, Peintinger F, Wan-Kau S et al (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25:2650\u20132655. https:\/\/doi.org\/10.1200\/JCO.2006.08.2271","journal-title":"J Clin Oncol"},{"key":"7697_CR16","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796\u20131804. https:\/\/doi.org\/10.1200\/JCO.2011.38.8595","journal-title":"J Clin Oncol"},{"key":"7697_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet"},{"key":"7697_CR18","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00432-021-03763-8","volume":"147","author":"R Chen","year":"2021","unstructured":"Chen R, Li S, Li Y et al (2021) Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China. J Cancer Res Clin Oncol 147:3495\u20133501. https:\/\/doi.org\/10.1007\/s00432-021-03763-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"7697_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB et al (2017) AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin 67:93\u201399. https:\/\/doi.org\/10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"7697_CR20","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol 38:1346\u20131366. https:\/\/doi.org\/10.1200\/JCO.19.02309","journal-title":"J Clin Oncol"},{"key":"7697_CR21","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"7697_CR22","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147\u20132159. https:\/\/doi.org\/10.1056\/NEJMoa1612645","journal-title":"N Engl J Med"},{"key":"7697_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-023-00525-2","volume":"9","author":"J Huober","year":"2023","unstructured":"Huober J, van Mackelenbergh M, Schneeweiss A et al (2023) Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. NPJ Breast Cancer 9:23. https:\/\/doi.org\/10.1038\/s41523-023-00525-2","journal-title":"NPJ Breast Cancer"},{"key":"7697_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C et al (2023) Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND Randomized Clinical Trial. JAMA Oncol 9:1557\u20131564. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3759","journal-title":"JAMA Oncol"},{"key":"7697_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918\u2013926. https:\/\/doi.org\/10.1001\/jama.2017.11470","journal-title":"JAMA"},{"key":"7697_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryden L et al (2024) Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med 390:1163\u20131175. https:\/\/doi.org\/10.1056\/NEJMoa2313487","journal-title":"N Engl J Med"},{"key":"7697_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455\u20131461. https:\/\/doi.org\/10.1001\/jama.2013.278932","journal-title":"JAMA"},{"key":"7697_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609\u2013618. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9","journal-title":"Lancet Oncol"},{"key":"7697_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33:258\u2013264. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07697-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T07:24:04Z","timestamp":1747553044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07697-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7697"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07697-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.S. has received honoraria for lectures and chairing sessions organized by Daiichi Sankyo, Eisai, Chugai, Kyowa Kirin, Eli Lilly, Pfizer, Taiho, AstraZeneca, and MSD. S.S. has received honoraria for lectures and chairing sessions organized by Daiichi Sankyo, Gilead Sciences, Chugai, Nipro, and Eli Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}